Living Cell Technologies Ltd (LCT) is an advanced biotechnology company currently listed on the Australian Stock Exchange. LCT’s focus is on market-driven encapsulated living cell products, for the treatment of Huntington's disease, haemophilia and insulin-dependent diabetes. LCT’s business was formed in 1987 to research cell extraction and to develop procedures for advanced living-cell replacement therapies.
Living Cell Technologies Limited
ASX:LCT ISIN:AU000000LCT6
新聞
2010年12月31日澳洲股市報告包括:Moly Mines (ASX:MOL)首批54,500噸鐵礦石已發往中國;Living Cell Technologies Limited (ASX:LCT)宣布籌資5,750,000澳元;OM Holdings Limited (ASX:OMH)拿到興建馬來西亞燒結和熔煉廠所需地塊;Perilya Limited (ASX:PEM)提高Broken Hill項目礦產資源量和礦石儲量。
澳洲股市前一天觸及六周高點後,週三開盤下挫,回吐出先前漲幅。 S&P/ASX200指數早盤下挫0.3%,報4558.1點, 綜合指數下跌0.28%, 報4573.8點。金融股和工業股下跌0.5%,材料股下挫0.4%。
###
104,523 公司背景瀏覽
- 本頁瀏覽人次: (過去7日: 21) (過去30日: 108) (自發布以來: 12429)